Dasatinib - CAS 302962-49-8
Catalog number:
302962-49-8
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C22H26ClN7O2S
Molecular Weight:
488.01
COA:
Inquire
Targets:
Bcr-Abl
Description:
Dasatinib, also known as BMS-354825, is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
BMS-354825
MSDS:
Inquire
1.Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib
Houssam Oweini • Zaher K. Otrock. Arch Gynecol Obstet (2011) 283:133–134
On January 2008, dasatinib (70 mg twice daily) was started. The patient tolerated treatment well with no significant side effects. He was being followed up regularly with blood studies. By the end of February 2009 he informed us that his wife had a successful delivery of a healthy baby boy after a full term pregnancy. The baby was 3.1 kg and 46 cm with no congenital anomalies. At the time of conception, the patient was receiving dasatinib 140 mg/day, and the cumulative dose of dasatinib was approximated 350 g. At the time of writing this report, the patient was doing well on dasatinib. His last evaluation showed that he was in complete hematological response with no molecular response (quantitative analysis of peripheral blood BCR-ABL mRNA levels using real-time polymerase chain reaction were 6.00E-2, relative expression ratio of bcr-abl to G6PDH (ROCHE Diagnostics, Light Cycler 2.0). His baby was 7 months old, and he was in good health.
2.H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia
Akihito Matsuoka • Naoto Takahashi • Masatomo Miura • Takenori Niiok. Cancer Chemother Pharmacol (2012) 70:351–352
Takahashi et al. recently reported in this journal that administration of an acid suppressant such as an H2-receptor antagonist (H2RA) and a proton pump inhibitor can decrease the absorption of dasatinib from the gastrointestinal tract, thereby resulting in a significant decrease in plasma dasatinib concentration. Here, we report a patient treated with dasatinib and H2RA famotidine whose plasma dasatinib concentration increased dramatically after the cessation of famotidine.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Bcr-Abl Products


CAS 895519-91-2 Flumatinib mesylate

Flumatinib mesylate
(CAS: 895519-91-2)

Flumatinib mesylate, a derivative of imatinib, is a multi-kinase inhibitor for c-Abl, PDGFRβ and c-Kit. It is currently in Phase I and II clinical trials in Chi...

CAS 778277-15-9 GNF-5

GNF-5
(CAS: 778277-15-9)

CAS 690206-97-4 ZM306416

ZM306416
(CAS: 690206-97-4)

ZM306416 is a vascular endothelial growth factor receptor (VEGFR) antagonist.

CAS 778270-11-4 GNF-2

GNF-2
(CAS: 778270-11-4)

CHMFL-ABL-053
(CAS: 1808287-83-3)

CHMFL-ABL-053 is a potent and orally available inhibitor of BCR-ABL (IC50 = 70nM) without inhibitory activity against c-KIT kinase that is a common target of BC...

CAS 1020172-07-9 Rebastinib

Rebastinib
(CAS: 1020172-07-9)

DCC-2036(Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR

CAS 302962-49-8 Dasatinib

Dasatinib
(CAS: 302962-49-8)

Dasatinib, also known as BMS-354825, is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and...

CAS 641571-10-0 Nilotinib

Nilotinib
(CAS: 641571-10-0)

Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM.

CAS 923288-90-8 Nilotinib monohydrochloride monohydrate

Nilotinib monohydrochloride monohydrate
(CAS: 923288-90-8)

Nilotinib monohydrochloride monohydrate is an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. It ...

CAS 887650-05-7 Bafetinib

Bafetinib
(CAS: 887650-05-7)

Bafetinib is a potent and selective dual Bcr-Abl/Lyn inhibitor, but it does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and ...

CAS 854001-07-3 Dasatinib hydrochloride

Dasatinib hydrochloride
(CAS: 854001-07-3)

Dasatinib hydrochloride is a potent and dual Abl/ Src inhibitor. It inhibits c-Kit (WT)/c-Kit (D816V).

CAS 943319-70-8 Ponatinib

Ponatinib
(CAS: 943319-70-8)

Ponatinib is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.

CAS 260415-63-2 PD-173955

PD-173955
(CAS: 260415-63-2)

PD-173955 is a src tyrosine kinase inhibitor. PD173955 inhibited Bcr-Abl-dependent cell growth. PD173955 showed cell cycle arrest in G(1). PD173955 has an IC(50...

CAS 1257628-77-5 GZD824

GZD824
(CAS: 1257628-77-5)

GZD824 potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC(50) values of 0.2 and 0.13 nM, respectively. It also display...

CAS 859212-16-1 Bafetinib

Bafetinib
(CAS: 859212-16-1)

Bafetinib, also known as INNO-406, is an orally bioavailable 2-phenylaminopyrimidine derivative with potential antineoplastic activity. Bafetinib specifically ...

CAS 484049-04-9 DPH

DPH
(CAS: 484049-04-9)

DPH is a potent cell permeable c-Abl activator. It binds and alters the conformation of the myristoyl binding site of c-Abl tyrosine kinase. DPH exhibits potent...

CAS 1492952-76-7 Asciminib

Asciminib
(CAS: 1492952-76-7)

Asciminib, also known as ABL001, is a potent and selective allosteric Bcr-Abl inhibitor. Asciminib inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.

CAS 839706-07-9 GNF-7

GNF-7
(CAS: 839706-07-9)

GNF-7 is a type-II T315I inhibitor. GNF-7 inhibits Ack1 and germinal center kinase (GCK). GNF-7 is among the first type-II inhibitors capable of inhibiting T315...

Chemical Structure

CAS 302962-49-8 Dasatinib

Quick Inquiry

Verification code

Featured Items